Esubaglutide ? Injection 1?mg × 2 Prefilled Pens | YinuoQing by Intellivive Biotech (YinNuo Pharma)

描述

Esubaglutide ? Injection Description

Product name: Esupagglutide ? injection (Yinoqing/Yinuo Pharmaceutical)
Packing specifications: 1mg (0.5ml)*2 (prefilled automatic injection pen) ? Product dosage form: injection ? Packaging unit: box
Approval number: National Medicine Standard S20250007 ? Drug code: 86984594000045
Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd.
Product barcode: 6977560070016

Esubaglutide ? injection (marketed as YinuoQing®, also recognized by YinNuo Pharma) is China’s first domestically developed human?derived ultra?long?acting GLP?1 receptor agonist, designed for once-weekly subcutaneous administration in adult type 2 diabetes patients?.

• Half-life: ~204 hours — among the longest globally for GLP?1 RAs?.

• Clinical efficacy: Monotherapy for 4 weeks reduces HbA1c by ~1.1%; over 24 weeks, single-agent HbA1c reduction: 2.2%; with metformin, ~1.8%?.

• Weight loss: Non-diabetic users lost ~4?kg after 4 weeks; 71% lost ?5% body weight?.

• Cardiometabolic benefits: Reduced blood pressure (~4.1?mmHg), total and LDL cholesterol improvements?.

• Convenience: Weekly dosing or even potentially biweekly, via easy-to-use injection pens?.

This product is a major milestone in metabolic therapeutic innovation, combining potent glycemic control, weight management, and user compliance with a single weekly injection?.

? Product Specifications

? Why Choose YinuoQing Esubaglutide ??

• ? Innovative biologic: China’s first human-derived, ultra-long-acting GLP?1 RA

• ? Extended half-life: Up to 204 hours for improved dosing compliance

• ? Strong clinical outcomes: Effective in HbA1c, weight loss, and cardiometabolic markers

• ? Lab-ready packaging: Precise dosing via prefilled pens, perfect for research

? Supporting Research & Market Context

• NMPA Approval: January 26, 2025 — Diamond milestone for China’s diabetes therapy innovations?.

• First Prescription Issued: February 2025 at Shanghai and Nanjing major hospitals?.

• Global Status: Third human-derived long-acting GLP?1 RA with domestic IP (behind USA’s dulaglutide and tirzepatide)?.

• Clinical Benefits: Notable HbA1c reduction, weight management, and metabolic risk improvements?zh.wikipedia.org.

? Related Research Compounds

• Semaglutide (Ozempic®) Pre-filled Pens

• Dulaglutide (Trulicity®) Autoinjectors

• Tirzepatide (Mounjaro®) Dual GIP/GLP?1 Agonist Pens

? Final Summary

YinuoQing Esubaglutide ? Injection (1?mg, 2 pens) is a powerful research-grade GLP?1 receptor agonist with a record-breaking half-life, strong metabolic efficacy, and lab-friendly auto-injector pens. Fully traceable, clinically supported, and NMPA-approved, it’s ideal for research involving diabetes, obesity, and metabolic health interventions.
?? Reminder: strictly for laboratory or analytical use only — not for human use.